Cover Image

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

Summary: Background: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in haemodialysis patients. Methods: In this...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paul Martin (Author), Sarah Gleeson (Author), Candice L. Clarke (Author), Tina Thomson (Author), Helena Edwards (Author), Katrina Spensley (Author), Paige Mortimer (Author), Stacey McIntyre (Author), Alison Cox (Author), Graham Pickard (Author), Liz Lightstone (Author), David Thomas (Author), Stephen P. McAdoo (Author), Peter Kelleher (Author), Maria Prendecki (Author), Michelle Willicombe (Author)
Format:	Book
Published:	Elsevier, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023)

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
by: Jaeeun Yoo, et al.
Published: (2023)

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
by: Suvimol Niyomnaitham, et al.
Published: (2024)

Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England
by: Nick J Andrews, et al.
Published: (2022)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022)

Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies
by: Chinonyerem O. Iheanacho, et al.
Published: (2022)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
by: Manabendra Basu, et al.
Published: (2024)

Erythrodermic psoriasis following ChAdOx1 nCOV-19 vaccination: A case report
by: Pei-Tzu Lin, et al.
Published: (2022)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
by: Natalie Teh, et al.
Published: (2021)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
by: Jonathan D. Ho, MBBS, DSc, DipDermpath, et al.
Published: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
by: Anupa Mary Job, et al.
Published: (2022)

Sarcoidosis and Polymethyl Methacrylate (PMMA) Granulomas following COVID-19 Vaccination (ChAdOx1): Successful Treatment with Tofacitinib
by: Mayra Ianhez, et al.
Published: (2024)

AZ arm: Delayed cutaneous reaction to ChAdOx1 nCoV-19 (AZD1222) vaccine
by: Wei-Kai Hung, et al.
Published: (2022)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
by: Karina Soboleva, et al.
Published: (2022)

Psoriasis flare following ChAdOx1-S/nCoV-19 vaccination in patients with psoriasis under biologic treatment
by: Jen-Ping Chao, et al.
Published: (2021)

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review
by: Homa Faghihi, et al.
Published: (2023)

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association
by: Laíssa Fiorotti Albertino, et al.
Published: (2022)

Evans' syndrome following vaccination with ChAdOx1 nCoV-19 in a patient with new-onset localized scleroderma
by: Thilo Gambichler, et al.
Published: (2022)

Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report
by: Joanna Bokel, et al.
Published: (2022)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
by: Thachanun Porntharukchareon, et al.
Published: (2023)

Incidence of early adverse events following covishield (ChAdOx1 nCoV-19) vaccination: A prospective study
by: Gajanan D Velhal, et al.
Published: (2022)

Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications
by: Soumya Swaroop Sahoo, et al.
Published: (2022)

A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters.
by: Neeltje van Doremalen, et al.
Published: (2019)

Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
by: Michael Makris, et al.
Published: (2022)

The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based studyResearch in context
by: Huyen A. Tran, et al.
Published: (2023)

ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal
by: Arun Gautam, et al.
Published: (2021)

Association between COVID-19 Vaccination (ChAdOx1-S) and Thromboembolic, Thrombocytopenic, Hemorrhagic Events: A Systematic Review and Meta-analysis of Analytical Epidemiological Studies
by: Raman S. Vaman, et al.
Published: (2024)

Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccine in an older patient: Minireview and a case report
by: Paulo Queiroz Luciano, et al.
Published: (2022)

Improved Symptoms of Peripheral Facial Nerve Palsy in ChAdOx1 nCoV-19 Vaccine Recipients Following Complex Korean Medicine Treatment
by: Woo Seok Jang, et al.
Published: (2022)

Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany
by: Thomas Thiele, et al.
Published: (2022)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac-ChAdOx1
by: Saipin Pongsatha, et al.
Published: (2023)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
by: Kriangkrai Tawinprai, et al.
Published: (2022)

Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
by: Vishakh C. Keri, et al.
Published: (2022)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023)

Pregnant and Breastfeeding Mothers Who Have Received the ChAdOx1 AstraZeneca COVID-19 Vaccine May Have Infants with an Increased Risk of Zinc Insufficiency and SCID Disease
by: Amr Ahmed, et al.
Published: (2023)

Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
by: Hassan M. Al-Emran, et al.
Published: (2022)

Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center
by: Yeon Jeong Jeong, et al.
Published: (2022)